Incresync 25/15 Tablets / Film-coated
Alogliptin (as benzoate), Pioglitazone (as HCl)
"25mg, 45mg"
TAKEDA PHARMACEUTICALS U.S.A., INC.
| Pack size | 28's (14's Blister x 2) |
|---|---|
| Dispensing mode | POM |
| Source | USA |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 246.50 AED |
Indications
Incresync 25/15 Tablets / Film-coated is used for:
ALOGLIPTIN
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
PIOGLITAZONE
Treatment of type ii diabetes mellitus
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
PIOGLITAZONE
Treatment of type ii diabetes mellitus
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Alogliptin (as benzoate), Pioglitazone (as HCl) :
Mechanism of Action
ALOGLIPTIN
Alogliptin inhibits dipeptidyl peptidase 4 (dpp-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (gip) and glucagon like peptide 1 ( glp-1). The inhibition of dpp-4 increases the amount of active plasma incretins which helps with glycemic control. Gip and glp-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. Glp-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying
PIOGLITAZONE
Pioglitazone acts as an agonist at peroxisome proliferator activated receptors (ppar) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of ppar-gamma receptors increases the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, pioglitazone both enhances tissue sensitivity to insulin and reduces hepatic gluconeogenesis. Thus, insulin resistance associated with type 2 diabetes mellitus is improved without an increase in insulin secretion by pancreatic A cells
Alogliptin inhibits dipeptidyl peptidase 4 (dpp-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (gip) and glucagon like peptide 1 ( glp-1). The inhibition of dpp-4 increases the amount of active plasma incretins which helps with glycemic control. Gip and glp-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. Glp-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying
PIOGLITAZONE
Pioglitazone acts as an agonist at peroxisome proliferator activated receptors (ppar) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of ppar-gamma receptors increases the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, pioglitazone both enhances tissue sensitivity to insulin and reduces hepatic gluconeogenesis. Thus, insulin resistance associated with type 2 diabetes mellitus is improved without an increase in insulin secretion by pancreatic A cells
Note
Incresync 25/15 "25mg, 45mg" Tablets / Film-coated manufactured by TAKEDA PHARMACEUTICALS U.S.A., INC.. Its generic name is Alogliptin (as benzoate), Pioglitazone (as HCl). Incresync 25/15 is availble in United Arab Emirates.
Farmaco UAE drug index information on Incresync 25/15 Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.